Lucid Historical Cash Flow
| LUCD Stock | USD 1.55 0.05 3.33% |
Analysis of Lucid Diagnostics cash flow over time is an excellent tool to project Lucid Diagnostics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 1.2 B or Capital Expenditures of 596.9 K as it is a great indicator of Lucid Diagnostics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Lucid Diagnostics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lucid Diagnostics is a good buy for the upcoming year.
Lucid |
About Lucid Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Lucid balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Lucid's non-liquid assets can be easily converted into cash.
Lucid Diagnostics Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Capital Expenditures
Capital Expenditures are funds used by Lucid Diagnostics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Lucid Diagnostics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Lucid Diagnostics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Lucid Diagnostics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.At present, Lucid Diagnostics' Net Borrowings is projected to increase significantly based on the last few years of reporting. The current year's Other Cashflows From Financing Activities is expected to grow to about 50.7 B, whereas Total Cash From Operating Activities is projected to grow to (41.9 B).
| 2022 | 2023 | 2024 | 2025 (projected) | Capital Expenditures | 908K | 221K | 646K | 596.9K | Depreciation | 1.9M | 2.5M | 1.2B | 1.2B |
Lucid Diagnostics cash flow statement Correlations
Click cells to compare fundamentals
Lucid Diagnostics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lucid Diagnostics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (45.1K) | 53.5M | (31.2M) | (3.6M) | 3.5B | 3.6B | |
| Other Cashflows From Financing Activities | 5.6M | 2.1M | 804K | 19.2M | 48.2B | 50.7B | |
| Total Cash From Operating Activities | (5.6M) | (17.7M) | (29.7M) | (32.8M) | (44.1B) | (41.9B) | |
| Change To Operating Activities | 1.6M | 1.4M | 1.7M | 9.2M | 10.5M | 11.1M | |
| Net Income | (8.3M) | (28.1M) | (56.2M) | (52.7M) | (45.5B) | (43.3B) | |
| Total Cash From Financing Activities | 5.6M | 72.1M | 2.6M | 29.5M | 48.2B | 50.7B | |
| End Period Cash Flow | 111.3K | 53.7M | 22.5M | 18.9M | 22.4B | 23.5B | |
| Change To Netincome | 173.9K | 65.5K | 9.6M | 13.9M | 15.9M | 16.7M | |
| Change To Liabilities | 301.9K | 1.1M | (665K) | 7.6M | 8.7M | 9.1M | |
| Investments | (10.3K) | (862K) | (4.1M) | (249K) | (646K) | (678.3K) | |
| Stock Based Compensation | 65K | 9.6M | 15.0M | 6.8M | 4.2B | 4.4B | |
| Free Cash Flow | (5.6M) | (18.5M) | (30.6M) | (33.0M) | (44.1B) | (41.9B) | |
| Change In Working Capital | 2.6M | 807K | 8.9M | 5.7M | (4.4M) | (4.2M) | |
| Begin Period Cash Flow | 156.4K | 111K | 53.7M | 22.5M | 18.9B | 19.8B | |
| Other Non Cash Items | (1.1M) | 10.5M | 653K | 4.9M | (4.0B) | (3.8B) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth 0.497 | Return On Assets | Return On Equity |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.